May 15, 2024:

The Big Ten Cancer Research Consortium (Big Ten CRC) is set to participate in the American Society of Clinical Oncology® (ASCO) 2024 Annual Meeting in Chicago from May 31 to June 4. During the event, three Big Ten CRC studies will be presented, working group meetings will take place, and the Big Ten CRC will host a joint reception with Hoosier Cancer Research Network (HCRN). The Big Ten CRC will also be represented in the exhibit hall at HCRN’s booth, #37113.

Study Presentations

Three Big Ten CRC studies, BTCRC-LUN18-153, BTCRC-GI22-564, and BTCRC-LUN16-081, will be presented during ASCO.

BTCRC-LUN18-153 is a randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm. The authors are Greg Durm, Muhammad Furqan, Richard Hall, Alberto Chiappori, Patrick Ma, Lawrence Feldman, Amit Kulkarni, Missak Haigentz, Apar Kishor Ganti, Dwight Owen, Rachel Sanborn, and Nasser Hanna.

BTCRC-GI22-564 is a phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC). The authors are John Ebben, Jens Eickhoff, Dustin Deming, Howard Hochster, Anita Turk, Vaibhav Sahai, and Nataliya Uboha.

BTCRC-LUN16-081 is a clinical trial comparing elderly vs nonelderly patients treated with consolidation nivolumab or nivolumab plus ipilimumab after chemoradiation for unresectable stage III NSCLC. The authors are Shobha Shahani, Sandra Althouse, Nasser Hanna, and Greg Durm.

Working Group Meetings

The Big Ten CRC will host in-person meetings for the Gastrointestinal, Thoracic, and Breast Cancer Clinical Trial Working Groups during ASCO 2024. For more information or to schedule time to meet with Administrative Headquarters staff members, please reach out to Jonathan Ang at jang@hoosiercancer.org, or stop by booth #37113.

Reception

Administrative Headquarters is hosting a combined reception for members of both the Big Ten CRC and Hoosier Cancer Research Network on Saturday, June 1 from 6:30 pm – 8:30 pm to celebrate 50 combined years of service to cancer research. The gathering will take place at voco Chicago Downtown, 350 W. Wolf Point Plaza, in the LaSalle Room. For more information, please contact Debbie Schlegel at dschlegel@hoosiercancer.org.

About the Big Ten Cancer Research Consortium: The Big Ten Cancer Research Consortium was created in 2013 to transform the conduct of cancer research through collaborative clinical trials and observational studies that seek to improve the lives of cancer patients in the diverse communities we serve by leveraging the scientific and clinical expertise of Big Ten universities. The Big Ten Cancer Research Consortium creates a unique team research culture to drive science rapidly from ideas to treatment and prevention. Within this innovative environment, today’s research leaders collaborate with and mentor the research leaders of tomorrow. Since its founding, the Big Ten CRC has activated nearly 40 clinical trials across a wide range of cancer types, more than 1,000 participants have enrolled in Big Ten CRC studies, and more than 500 researchers have joined Big Ten CRC Clinical Trial Working Groups.

About the Big Ten Conference: The Big Ten Conference is an association of world-class universities whose member institutions share a common mission of research, graduate, professional and undergraduate teaching and public service. Founded in 1896, the Big Ten has sustained a comprehensive set of shared practices and policies that enforce the priority of academics in the lives of students competing in intercollegiate athletics and emphasize the values of integrity, fairness and competitiveness. The broad-based programs of the 18 Big Ten institutions provide direct financial support for more than 11,000 participation opportunities on 350 teams in 42 different sports. The Big Ten sponsors 28 official conference sports, 14 for men and 14 for women. For more information, visit www.bigten.org.